Buprenorphine vs. Methadone vs. Naltrexone: Which Treatment Does What?

If you or someone you love is seeking treatment for opioid use disorder, you will encounter three main medications: buprenorphine, methadone, and naltrexone. All three are FDA-approved. All three have solid evidence behind them. But they work through completely different mechanisms, have different access requirements, and suit different situations.

Choosing between buprenorphine, methadone, and naltrexone is not about which one is better overall. It is about which one matches your specific pattern of use, your medical history, your living situation, and your goals. This guide explains what each medication does and when each one makes sense.

Quick Summary Before You Read On

• Buprenorphine: partial opioid agonist, can be prescribed by any certified doctor, taken at home
• Methadone: full opioid agonist, only dispensed through federally licensed opioid treatment programs (OTPs), daily clinic visits required
• Naltrexone: opioid antagonist, no opioid effect, requires full detox before starting, available as a monthly injection
• All three significantly reduce overdose death risk compared to no treatment
• Medication-assisted treatment with any of the three is more effective than behavioral treatment alone

Buprenorphine (Suboxone, Subutex)

How It Works

Buprenorphine is a partial opioid agonist. It activates opioid receptors in the brain, but not fully. This partial activation is enough to prevent withdrawal and significantly reduce cravings without producing the intense high of a full agonist like fentanyl or heroin.

A key safety feature of buprenorphine is its “ceiling effect.” Above a certain dose, increasing the amount of buprenorphine does not increase its effects. This makes overdose from buprenorphine alone much less likely than with full agonists. Most formulations (Suboxone) also contain naloxone to deter injection misuse.

Who It Suits Best

Buprenorphine is a strong first-line choice for most people with opioid use disorder. It is particularly well-suited for:

• People who can reliably take a daily medication at home
• People who want more flexibility than daily clinic visits allow
• People with employment or family commitments that make daily clinic attendance difficult
• People who are motivated and stable enough to manage medication at home safely

Access and Availability

Since the removal of the DATA 2000 waiver requirement in 2023, any licensed physician, nurse practitioner, or physician assistant in the US can prescribe buprenorphine for opioid use disorder without special certification. This opened up access dramatically. You can now receive a buprenorphine prescription from your primary care doctor, an urgent care clinic, a telehealth provider, or many emergency departments.

Monthly injectable buprenorphine (Sublocade) is also available for people who prefer not to manage daily medication.

“Buprenorphine treatment reduces opioid overdose deaths by approximately 50 percent compared with no treatment.” — SAMHSA Treatment Improvement Protocol 63

Methadone

How It Works

Methadone is a full opioid agonist with a very long half-life of 24 to 36 hours. It fully activates opioid receptors and stays in the system long enough to provide stable coverage throughout the day, preventing withdrawal and reducing cravings without causing the rapid peaks and crashes associated with shorter-acting opioids.

Because it is a full agonist, methadone does have a risk of misuse and overdose, particularly during the first weeks of treatment when the appropriate dose for an individual has not yet been established. This is why it requires daily supervised dosing in an opioid treatment program, at least initially.

Who It Suits Best

Methadone is often the most appropriate choice for:

• People with severe, long-standing opioid use disorder who have not responded to buprenorphine
• People with high opioid tolerance who need stronger receptor activation for adequate symptom control
• People who benefit from the daily structure and accountability of clinic visits
• People who prefer a medication they do not need to manage at home (reduces household diversion risk)
• Pregnant women, for whom methadone has a longer safety track record, though buprenorphine is also used

Access and Limitations

Methadone for opioid use disorder must be dispensed through federally licensed opioid treatment programs. You cannot get it from a regular doctor’s office. You typically have to visit the clinic daily for dosing, at least until you have earned “take-home” privileges by demonstrating stability, usually several months into treatment.

This daily requirement is both a limitation and a feature. It limits access for people who live far from an OTP or have transportation challenges. But for people who need structure and monitoring, the daily contact with a treatment team is beneficial.

Naltrexone (Vivitrol)

How It Works

Naltrexone is an opioid antagonist. Unlike buprenorphine and methadone, it does not activate opioid receptors at all. It blocks them. If you use an opioid while taking naltrexone, you will not feel the effect because the drug cannot bind to its receptors.

Naltrexone has no opioid effect, no dependence potential, and no abuse potential. Because it is not a controlled substance, prescribing it requires no special registration. The monthly injectable form (Vivitrol) is particularly useful because once it is administered, the protection lasts the entire month regardless of whether the person remembers to take a daily pill.

The Critical Requirement

You must be fully detoxed from opioids before starting naltrexone. If there are any opioids in your system when you start, naltrexone will precipitate acute, severe withdrawal immediately. This is not just uncomfortable. It can be dangerous. A complete detox period of at least 7 to 10 days for short-acting opioids, and 10 to 14 days for methadone, is required before starting naltrexone.

This requirement is the primary limitation of naltrexone. For people who are physically dependent, the detox period is a difficult barrier. Relapse rates during the detox-waiting period before naltrexone can be high.

Who It Suits Best

• People who have already completed detox and are motivated to maintain abstinence
• People who prefer a non-opioid medication option for personal or professional reasons
• People in professions where controlled substance prescriptions may create issues (healthcare workers, pilots, certain licensed professionals)
• People who want monthly rather than daily medication management
• People in criminal justice settings or coming out of incarceration where controlled medications may not be available

“Extended-release naltrexone is as effective as buprenorphine-naloxone in preventing opioid relapse among patients who have successfully completed detox. The challenge is completing detox.” — New England Journal of Medicine, 2018

Side-by-Side Comparison

• Opioid Effect: Buprenorphine = partial; Methadone = full; Naltrexone = none
• Overdose Potential: Buprenorphine = low; Methadone = moderate; Naltrexone = none
• Requires Detox First: Buprenorphine = mild withdrawal required; Methadone = no; Naltrexone = full detox required
• Prescription Access: Buprenorphine = any licensed prescriber; Methadone = OTP clinic only; Naltrexone = any prescriber
• Forms Available: Buprenorphine = daily film or monthly injectable; Methadone = daily clinic dose; Naltrexone = daily pill or monthly injectable
• Best For: Buprenorphine = most people with OUD; Methadone = severe OUD or OTP preference; Naltrexone = post-detox abstinence support

What the Research Shows About All Three

All three medications have been studied in large clinical trials and consistently outperform placebo and behavioral therapy alone in reducing opioid use, preventing overdose, and improving treatment retention. A 2023 meta-analysis in JAMA Psychiatry confirmed that medication-assisted treatment reduces opioid overdose deaths by 32 to 68 percent depending on the medication and population studied.

The best medication is the one a person will actually take and stay on. Treatment retention is more predictive of outcomes than the specific medication chosen. Starting one medication and switching if it is not working is a legitimate approach and happens regularly in clinical practice.

How to Decide

The decision between these three medications is best made with a doctor who knows your full history. These are the questions worth discussing:

• How long have you been using opioids and in what quantity?
• Have you tried medication-assisted treatment before? What happened?
• Do you have a stable living situation and reliable daily routine?
• What does your support system look like?
• Are there professional or legal considerations that affect which medications are practical?
• What are your goals: harm reduction, controlled use, or abstinence?

If you need help finding a provider who offers these treatments, the SAMHSA Buprenorphine Practitioner Locator (findtreatment.gov) allows you to search by zip code for doctors in your area. For methadone, SAMHSA’s OTP Locator (opioidtreatmentlocator.hhs.gov) lists licensed clinics. For naltrexone, any GP or psychiatrist can prescribe it with a regular office visit.